Compare EDD & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EDD | BNTC |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.7M | 411.4M |
| IPO Year | N/A | 2020 |
| Metric | EDD | BNTC |
|---|---|---|
| Price | $5.65 | $13.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $27.67 |
| AVG Volume (30 Days) | ★ 494.8K | 100.6K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 7.52% | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.57 | $9.85 |
| 52 Week High | $6.18 | $17.15 |
| Indicator | EDD | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 60.55 | 74.41 |
| Support Level | $5.44 | $12.79 |
| Resistance Level | $5.68 | $14.21 |
| Average True Range (ATR) | 0.13 | 0.75 |
| MACD | 0.07 | 0.36 |
| Stochastic Oscillator | 96.62 | 96.77 |
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.